COVID-19

Awakn Life Sciences Enters Global Licensing Agreement For Proprietary Sublingual S-Ketamine Formulation With LTS

Agreement Includes Exclusive Rights for Treatment of Addiction, Anxiety and Eating DisordersAlso Includes Access to Phase 1 Data and Patents…

7 months ago

CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

Validity of CureVac patent EP 1 857 122 B1 denied by German Federal Patent Court after nullity action filed by…

7 months ago

Optimind Pharma Provides Corporate Update

TORONTO, ON / ACCESSWIRE / December 19, 2023 / Optimind Pharma Corp. (CSE:OMND) ("Optimind" or the "Company"), an emerging provider…

7 months ago

TransCon™ hGH (lonapegsomatropin) Achieved Statistically Superior Outcomes Compared to Placebo in Phase 3 foresiGHt Trial of Adults with Growth Hormone Deficiency

–   On primary efficacy and key secondary endpoints, TransCon hGH demonstrated statistically significant reduction from baseline in trunk fat and…

7 months ago

BioStem Technologies Appoints Executive Leader Patrick Daly to Board of Directors

POMPANO BEACH, Fla., Dec. 19, 2023 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused…

7 months ago

Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees

Hermann Bantleon GmbH (“Bantleon), Shareholder of German AVIA, will Offer the ColoAlert® At-Home Screening Test to Employees Across All Three…

7 months ago

Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission

CAMBRIDGE, Mass., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the European Commission has revoked…

7 months ago

XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® Royalties

Low-cost financing capitalizes on XOMA’s $14 million acquisition of VABYSMO® (faricimab) royalties in 2021 Proceeds expected to be used for stock…

7 months ago

BioCryst Announces Publication of Data from Open-label Extension of the APeX-2 Pivotal Trial of ORLADEYO® (berotralstat)

– Results published in JACI: In Practice show rapid and sustained reductions in HAE attacks and improved quality of life…

7 months ago

Masimo Receives FDA Clearance for Stork™ Baby Monitoring System

Stork Provides Continuous Monitoring of Oxygen Saturation, Pulse Rate, and Skin Temperature, with Alarms, for Sick and Healthy Babies at…

7 months ago